Replies to post #255784 on Biotech Values

[jbog]

Vertex

This is next up in their pipeline;

For type 1 diabetes, Kewalramani said zimislecel will soon complete pivotal study enrollment, supporting global regulatory submissions in 2026. Data showed all 12 patients with at least one year of follow-up achieved target outcomes, with 10 of 12 insulin-free at 12 months.

What's that possibly worth?

Zimislecel, also known as VX-880, is an experimental allogeneic stem cell-derived islet cell therapy developed by Vertex Pharmaceuticals for treating type 1 diabetes. It is designed to restore the pancreas's ability to produce insulin, potentially eliminating or significantly reducing the need for exogenous insulin injections. The therapy involves infusing fully differentiated, insulin-producing islet cells into the liver's portal vein, where they engraft and begin producing insulin

[dewophile]

congrats VRTX has been on a multi year tear - all starting with the CF drugs which were an afterthought to their lead focus in hep C